Clinical Research
Activating mutations in PIK3CA (the gene encoding the p110α catalytic subunit of class I phosphatidylinositol 3-kinase [PI3K] [PI3Kα]) lead to increased activity of the PI3K pathway and play a role in endocrine treatment resistance in breast cancer.
Dirk Schadendorf, MD, Reinhard Dummer, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario Mandalà, MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Christine-Elke Ortmann, MS, Egbert de Jong, MD, Eduard Gasal, MD, Richard Kefford, MD, PhD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
In the COMBI-AD trial (NCT01682083), 12 months of adjuvant D+T led to significant improvement of RFS versus PBO (hazard ratio [HR], 0.47; P <.001) in pts with resected BRAF V600–mutant stage III melanoma; 3- and 4-year RFS rates were 59% and 54%, respectively.
Sami Diab, MD, Hope S. Rugo, MD, Lida A. Mina, MD, Shannon Puhalla, MD, Reshma Mahtani, DO, N. Lynn Henry, MD, PhD, Neelima Denduluri, MD, Denise Yardley, MD, Yao Wang, MD, Lillian Shahied Arruda, PhD, Iulia C. Tudor, PhD, Eric Gauthier, PharmD, PhD, Akos Czibere, MD, PhD, Jennifer K. Litton, MD, Sara A. Hurvitz, MD
Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2-negative germline BRCA1/2-mutated (gBRCA1/2mut) locally advanced/metastatic breast cancer.
Evidence exists showing that enabling patients to engage in treatment decisions through education and shared decision-making is an effective tool in promoting self-efficacy, reducing barriers to care, and increasing the perceived benefits of self-involvement in one’s cancer diagnosis and treatment plan.
Julia Vandross, NP-BC, BSN, MSN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Tina DeNofrio, RN, BSN, OCN
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for the delivery of androgen deprivation therapy (ADT) in prostate cancer (PCa).
Maria Badillo, MSN, RN, Diana Nava, RN, Maria de la Rosa, Wendy Chen, PA, Maria Guerrero, DNP, MS, RN, Michael Wang, MD
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.
Hairy cell leukemia (HCL) is a rare B-cell malignancy, diagnosed in ~1000 new patients a year in the US.
Jillian Settlemire, RN, Jocelyn E. Bushart, ANP-BC, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, David Arthur, PhD, Paul Barr, MD, Steven Coutre, MD
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK), is approved in the US for the treatment of CLL/SLL and allows for treatment without chemotherapy.
Shelbi Burtt BSN, RN, OCN, Jessica Scott, RN, BSN, OCN, Cathy Zhou, MS, Lori Styles, MD, David Arthur, PhD, Bertrand Anz, MD, Ian W. Flinn, MD, PhD
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the US for CLL/SLL treatment, including in combination with obinutuzumab.
Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/K–mutant stage III melanoma.